10x Genomics 관리

관리 기준 확인 3/4

10x Genomics CEO는 Serge Saxonov, Jul2012 에 임명되었습니다 의 임기는 12.33 년입니다. 총 연간 보상은 $ 8.29M, 6.6% 로 구성됩니다. 6.6% 급여 및 93.4% 보너스(회사 주식 및 옵션 포함). 는 € 57.17M 가치에 해당하는 회사 주식의 3.32% 직접 소유합니다. 57.17M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 5.4 년입니다.

주요 정보

Serge Saxonov

최고 경영자

US$8.3m

총 보상

CEO 급여 비율	6.6%
CEO 임기	12.3yrs
CEO 소유권	3.3%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Serge Saxonov 의 보수는 10x Genomics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$183m
Jun 30 2024	n/a	n/a	-US$240m
Mar 31 2024	n/a	n/a	-US$264m
Dec 31 2023	US$8m	US$545k	-US$255m
Sep 30 2023	n/a	n/a	-US$223m
Jun 30 2023	n/a	n/a	-US$172m
Mar 31 2023	n/a	n/a	-US$174m
Dec 31 2022	US$19m	US$504k	-US$166m
Sep 30 2022	n/a	n/a	-US$167m
Jun 30 2022	n/a	n/a	-US$142m
Mar 31 2022	n/a	n/a	-US$89m
Dec 31 2021	US$12m	US$430k	-US$58m
Sep 30 2021	n/a	n/a	-US$455m
Jun 30 2021	n/a	n/a	-US$504m
Mar 31 2021	n/a	n/a	-US$533m
Dec 31 2020	US$11m	US$400k	-US$543m
Sep 30 2020	n/a	n/a	-US$134m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$2m	US$394k	-US$31m
Sep 30 2019	n/a	n/a	-US$100m
Jun 30 2019	n/a	n/a	-US$105m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$1m	US$366k	-US$112m

보상 대 시장: Serge 의 총 보상 ($USD 8.29M )은 German 시장( $USD 1.65M ).

보상과 수익: Serge 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Serge Saxonov (47 yo)

12.3yrs

테뉴어

US$8,286,050

보상

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

리더십 팀

이름	위치	테뉴어	보상	소유권
Serge Saxonov	Co-Founder	12.3yrs	US$8.29m	3.32% € 57.2m
Benjamin Hindson	Co-Founder	12.3yrs	US$4.43m	2.68% € 46.0m
Eric Whitaker	Chief Legal Officer	7.3yrs	US$3.88m	0.12% € 2.0m
Adam Taich	CFO, Treasurer	less than a year	데이터 없음	데이터 없음
Jim Goodrich	Chief of Global Operations	less than a year	데이터 없음	데이터 없음
Michael Schnall-Levin	Founding Scientist & CTO	2.8yrs	데이터 없음	데이터 없음
Alexander Wong	Chief Information Officer	less than a year	데이터 없음	데이터 없음
Cassie Corneau	Manager of Investor Relations & Strategic Finance	no data	데이터 없음	데이터 없음
Rebecca Port	Chief People Officer	3.8yrs	데이터 없음	데이터 없음
Mennah Moustafa	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음
Jens Durruthy	Associate Director of Product Management	no data	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

48.5yo

평균 연령

경험이 풍부한 관리: 1KJ 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Serge Saxonov	Co-Founder	12.3yrs	US$8.29m	3.32% € 57.2m
Benjamin Hindson	Co-Founder	12.3yrs	US$4.43m	2.68% € 46.0m
Kimberly Popovits	Independent Director	4.7yrs	US$338.71k	0.0038% € 65.5k
John Stuelpnagel	Independent Chairman	11.3yrs	US$403.59k	2.02% € 34.7m
Shehnaaz Suliman	Independent Director	5.3yrs	US$336.39k	0.0038% € 65.5k
Alan Mateo	Director	less than a year	데이터 없음	데이터 없음
Sridhar Kosaraju	Independent Director	5.6yrs	US$346.39k	0.029% € 503.6k
Sarah Polonius-Teichmann	Director	less than a year	데이터 없음	데이터 없음

5.4yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 1KJ 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

10x Genomics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

10x Genomics, Inc., Annual General Meeting, Jun 11, 2024

James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024

Chief Commercial Officer recently sold €566k worth of stock

Chief Commercial Officer recently sold €409k worth of stock

10X Genomics, Inc. Announces Board Changes

Independent Chairman recently sold €512k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.79 loss in 3Q 2023)

10x Genomics, Inc. Announces Launch of Two New Chromium Products Intends to Democratize Access to Single Cell Analysis - GEM-X Flex and GEM-X Universal Multiplex

10x Genomics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

New major risk - Share price stability

10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments

New major risk - Share price stability

New minor risk - Shareholder dilution

Second quarter 2024 earnings released

10X Genomics, Inc. Revises Earnings Guidance for Full Year 2024

10x Genomics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium

10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.50 loss per share (vs US$0.44 loss in 1Q 2023)

10x Genomics, Inc., Annual General Meeting, Jun 11, 2024

10x Genomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay

10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products

Full year 2023 earnings released: US$2.18 loss per share (vs US$1.46 loss in FY 2022)

10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024

10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

10x Genomics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Chief Commercial Officer recently sold €566k worth of stock

10X Genomics, Inc. Raises Revenue Guidance for Full Year 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$0.37 loss in 3Q 2022)

10X Genomics, Inc. Announces Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

10x Genomics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

10x Genomics, Inc. Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit

10X Genomics, Inc. Announces Use of Its Technologies in A Study Published in the Journal of Clinical Investment

Chief Commercial Officer recently sold €409k worth of stock

10x Genomics, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.57 loss in 2Q 2022)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

10X Genomics, Inc. Announces Board Changes

New minor risk - Share price stability

10x Genomics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vizgen, Inc. Provides Update on Litigation

10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Index

Independent Chairman recently sold €512k worth of stock

Co-Founder recently sold €133k worth of stock

10X Genomics, Inc. Revises Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2022)

Forecast to breakeven in 2025

Now 20% undervalued

Forecast to breakeven in 2025

Co-Founder recently sold €87k worth of stock

Full year 2022 earnings released: US$1.46 loss per share (vs US$0.53 loss in FY 2021)

10x Genomics, Inc. Provides Revenue Guidance for the Full Year 2023

10x Genomics, Inc. to Report Q4, 2022 Results on Feb 15, 2023

10x Genomics, Inc. Launches Xenium Platform for In Situ Analysis

Co-Founder recently sold €89k worth of stock

Insufficient new directors

10X Genomics, Inc. Announces Commercial Availability of BEAM

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.15 loss in 3Q 2021)

10X Genomics, Inc. Provides Revenue Guidance for Full Year 2022

10x Genomics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Insufficient new directors

Co-Founder recently sold €96k worth of stock

No longer forecast to breakeven

10X Genomics, Inc. Provides Earnings Guidance for the Third Quarter of 2022 and Full Year 2022

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.10 loss in 2Q 2021)

Forecast breakeven date moved forward to 2023

10x Genomics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

10x Genomics Inc. Advances Leadership and Innovation in Single Cell and Spatial Technologies At 2022 AGBT General Meeting

Co-Founder recently sold €121k worth of stock